Efficacy of the Anthracycline-Free Neoadjuvant Regimen of Pembrolizumab and Carboplatin Plus Docetaxel in TNBC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial
JAMA Oncol 2023 Nov 22;[EPub Ahead of Print], P Sharma, SR Stecklein, R Yoder, JM Staley, K Schwensen, A O'Dea, L Nye, D Satelli, G Crane, R Madan, MF O'Neil, J Wagner, KE Larson, C Balanoff, L Kilgore, MA Phadnis, AK Godwin, R Salgado, QJ Khan, J O'ShaughnessyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.